Trial
NCT04914897
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Merck Sharp & Dohme LLC
Condition
Pleural Mesothelioma
Intervention
THOR-707
Why stopped
Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-02